{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antipsychotic+Agents",
    "query": {
      "condition": "Antipsychotic Agents"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 220,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Antipsychotic+Agents&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:45:21.049Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00515723",
      "title": "Glucose and Lipid Metabolism on Antipsychotic Medication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Type 2 Diabetes Mellitus",
        "Hyperglycemia"
      ],
      "interventions": [
        {
          "name": "risperidone",
          "type": "DRUG"
        },
        {
          "name": "olanzapine",
          "type": "DRUG"
        },
        {
          "name": "quetiapine",
          "type": "DRUG"
        },
        {
          "name": "ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 96,
      "start_date": "2001-09",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2019-10-02",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00515723"
    },
    {
      "nct_id": "NCT05857566",
      "title": "Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug-induced Weight Gain"
      ],
      "interventions": [
        {
          "name": "RDX-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Response Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-05-16",
      "completion_date": "2023-09-13",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 1,
      "location_summary": "Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05857566"
    },
    {
      "nct_id": "NCT04922593",
      "title": "Relative Bioavailability of LY03010 Compared to Listed Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Psychotic Disorders",
        "Mood Disorders",
        "Schizophrenia Spectrum",
        "Mental Disorders",
        "Antipsychotic Agents",
        "Tranquilizing Agents",
        "Central Nervous System Depressants",
        "Physiological Effects of Drugs",
        "Psychotropic Drugs",
        "Neurotransmitter Agents",
        "Molecular Mechanisms of Pharmacological Action"
      ],
      "interventions": [
        {
          "name": "LY03010; paliperidone palmitate",
          "type": "DRUG"
        },
        {
          "name": "INVEGA SUSTENNA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 281,
      "start_date": "2021-01-13",
      "completion_date": "2022-04-15",
      "has_results": false,
      "last_update_posted_date": "2023-04-25",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 9,
      "location_summary": "Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04922593"
    },
    {
      "nct_id": "NCT06997198",
      "title": "Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Tardive Dyskinesia",
        "Intellectual Disability",
        "Developmental Disabilities"
      ],
      "interventions": [
        {
          "name": "Deutetrabenazine Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 25,
      "start_date": "2026-05-01",
      "completion_date": "2027-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06997198"
    },
    {
      "nct_id": "NCT00922272",
      "title": "Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia and Predominant Negative Symptoms"
      ],
      "interventions": [
        {
          "name": "SPD489 (lisdexamfetamine dimesylate)",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching SPD489 (lisdexamfetamine dimesylate)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 92,
      "start_date": "2009-09-14",
      "completion_date": "2011-01-20",
      "has_results": true,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 27,
      "location_summary": "Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 21 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00922272"
    },
    {
      "nct_id": "NCT00412373",
      "title": "Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizoaffective Disorder",
        "Psychotic Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Paliperidone ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 307,
      "start_date": "2006-12",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2014-05-09",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 15,
      "location_summary": "Cerritos, California • Costa Mesa, California • Garden Grove, California + 12 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Pico Rivera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00412373"
    },
    {
      "nct_id": "NCT02282761",
      "title": "A Trial to Assess the Antipsychotic Efficacy of ITI-007",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ITI-007",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intra-Cellular Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 450,
      "start_date": "2014-11",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02282761"
    },
    {
      "nct_id": "NCT01211522",
      "title": "The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Delirium",
        "Impaired Cognition",
        "Long Term Psychologic Disorders"
      ],
      "interventions": [
        {
          "name": "Haloperidol",
          "type": "DRUG"
        },
        {
          "name": "Ziprasidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 566,
      "start_date": "2011-12-14",
      "completion_date": "2018-07-19",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 16,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01211522"
    },
    {
      "nct_id": "NCT01716975",
      "title": "Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia",
        "Impaired Cognition"
      ],
      "interventions": [
        {
          "name": "EVP-6124",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FORUM Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 767,
      "start_date": "2012-10",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-05-03",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 49,
      "location_summary": "Phoenixville, Arizona • Little Rock, Arkansas • Cerritos, California + 46 more",
      "locations": [
        {
          "city": "Phoenixville",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01716975"
    },
    {
      "nct_id": "NCT00288366",
      "title": "Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizoaffective Disorder",
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "ziprasidone vs. aripiprazole",
          "type": "DRUG"
        },
        {
          "name": "aripiprazole vs. ziprasidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 49,
      "start_date": "2006-01",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-06",
      "last_synced_at": "2026-05-22T09:45:21.049Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288366"
    }
  ]
}